Advanced Prostate Cancer
Conditions
Brief summary
The study includes the recruitment of patients with advanced prostate cancer resistant to chemical castration This is a multicenter prospective trial randomized phase III
Detailed description
The study includes the recruitment of patients with advanced prostate cancer resistant to chemical castration This is a multicenter prospective trial randomized phase III This study design that includes a double randomizzzazione aims generally demonstrating non-inferiority in terms of survival of the suspension dell'ormonoterapia versus the maintenance and / or administration of intermittent versus continuous administration of chemotherapy in patients with prostate cancer resistant to chemical castration I started to line chemotherapy with Docetaxel.
Interventions
DRUGDocetaxel
Docetaxel will be administered at a dose of 75 mg/m2 per square meter as a 1-hour intravenous infusion on day 1 every 21 days in association to 5 mg of prednisone orally twice daily. In patients randomised to arms B up to 10 cycles of docetaxel will be planned, in association to stopping LH-RH analogues.
DRUGDocetaxel + LH-RH analogues
Docetaxel will be administered at a dose of 75 mg/m2 per square meter as a 1-hour intravenous infusion on day 1 every 21 days in association to 5 mg of prednisone orally twice daily. In patients randomised to arms A up to 10 cycles of docetaxel will be planned in association to maintenance of LH-RH analogues administration.
DRUGContinuous Docetaxel
Patients randomised in the arms AB2 (continuous docetaxel) will continue treatment up to ten cycles after even if their PSA level at 4 cycles will be reduced \>50% or will reach a level \<4 ng/mL.
Sponsors
University of Turin, Italy
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. age over 18 years, 2. histologically documented adenocarcinoma of the prostate, 3. written informed consent to the study, 4. Castrate resistant metastatic prostate cancer in the presence of castrate levels of testosterone (\<50 ng/ml) and eligible to docetaxel chemotherapy. The condition of castrate resistant prostate cancer is the defined either as the documentation of a new metastasis or PSA increase more than 50% or increase more than 25% from a lower PSA value during previous hormone therapy in case of disease response or stabilization to previous hormone therapy, respectively. Absolute PSA increase should be greater than 5 ng/ml, 5. an elevated PSA level must have been documented within 4 weeks of initiating docetaxel chemotherapy, 6. more than 4 weeks since major surgery and fully recovered, 7. more than 4 weeks since any prior radiation with any toxicity attributable to radiation resolved to grade 1 or less, 8. more than 8 weeks since the last dose of strontium or samarium, 9. ECOG Performance Status more than/equal to 2, 10. life expectancy \>6 months, 11. required initial laboratory values: absolute neutrophil count \> 1500/ul Platelets \> 100,000/ul., Hemoglobin \> 8.0 g/dl, Creatinine, SGOT, SGPT less than 2.0 X upper limit of normal, Bilirubin less than/equal to upper limit of normal (ULN). 12. Appropriate patient compliance
Exclusion criteria
1. Patients with increased serum PSA levels with negative bone scan and CT scan. 2. Prior systemic chemotherapy for prostate cancer. Prior neoadjuvant or adjuvant chemotherapy is permitted if there was no evidence of disease relapse within 12 months of the last dose of chemotherapy, 3. Peripheral neuropathy \>grade 1, 4. myocardial infarction or significant change in anginal pattern within the last 6 months, symptomatic congestive heart failure (NYHA Class III or higher) or uncontrolled cardiac arrhythmia, 5. patients with a history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80, 6. poorly controlled diabetes (fasting blood glucose \>250) despite optimization of medical therapy, peptic ulcers or other contraindications to steroid therapy, 7. previous history of malignant disease with the exception of non melanoma skin cancer curatively treated, 8. significant neurologic or psychiatric diseases preventing patients to give a valid informed consent, 9. brain metastases, 10. prisoner status 11. because patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy, HIV-positive patients receiving combination anti-retroviral therapy are excluded. \-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| overall survival | six years | The primary aim of the study will be the demonstration of non inferiority in terms of overall survival of stopping androgen deprivation therapy (arm B) versus maintenance androgen deprivation therapy (arms A) and intermittent docetaxel therapy (arm AB1) versus continuous docetaxel therapy (arms AB2) up to ten cycles. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Toxicity | six years | Toxicity graded according to NCI Criteria |
| Progression free survival | six years | Progression free survival measured according to Prostate Cancer Clinical Trials Working Group |
| Quality of life | six years | Quality of life evaluated according to FACT-P questionnaire |
| Pain | six years | Pain response evaluated by Mc-Gill Pain Questionnaire |
| Cost Analysis | six years | A cost minimization analysis will be performed in order to find if there is a treatment strategy that may achieve the same outcome for least cost. The analysis will focus on the direct medical costs of each treatment, collected at patient level. |
Countries
Italy
Outcome results
None listed